DeepMed Research

Izalontamab brengitecan

Generic Name: Izalontamab brengitecan

Clinical Trials

A Study of SI-B003 or BL-B01D1+SI-B003 in Patients With Unresectable Locally Advanced or Recurrent Metastatic HER2 Negative Breast Cancer

Phase 2

Recruiting

Conditions: Breast Cancer

Interventions: Drug: BL-B01D1
Drug: SI-B003

First Posted Date: 2023-09-21

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 58

Registration Number: NCT06042894

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: BL-B01D1
Drug: SI-B003

First Posted Date: 2023-08-23

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 186

Registration Number: NCT06006169

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors

Phase 2

Recruiting

Conditions: Colorectal Cancer
Gastric Cancer
Esophageal Cancer

Interventions: Drug: SI-B003
Drug: BL-B01D1
Drug: PD-1 Monoclonal Antibody

First Posted Date: 2023-08-23

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 268

Registration Number: NCT06008054

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies

Phase 2

Recruiting

Conditions: Cervical Cancer

Interventions: Drug: BL-B01D1
Drug: SI-B003

First Posted Date: 2023-08-14

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 130

Registration Number: NCT05990803

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Phase 1

Recruiting

Conditions: Small Cell Lung Cancer
NSCLC
Lung Cancer
NPC
Non Small Cell Lung Cancer
Esophageal Cancer
Nasopharyngeal Cancer
Breast Cancer
SCLC

Interventions: Drug: BL-B01D1

First Posted Date: 2023-08-09

Last Posted Date: 2024-07-22

Lead Sponsor: SystImmune Inc.

Target Recruit Count: 260

Registration Number: NCT05983432

Locations: 🇺🇸
SystImmune Recruiting Center, Houston, Texas, United States
🇪🇸
SystImmune Recruiting Site, Madrid, Spain

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid Tumors

Phase 2

Recruiting

Conditions: Urothelial Carcinoma
Solid Tumor

Interventions: Drug: BL-B01D1
Drug: SI-B003

First Posted Date: 2023-07-28

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 52

Registration Number: NCT05965856

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer
Nasopharyngeal Carcinoma

Interventions: Drug: BL-B01D1
Drug: SI-B003

First Posted Date: 2023-07-21

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 121

Registration Number: NCT05956587

Locations: 🇨🇳
Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳
Liuzhou People's Hospital, Liuzhou, Guangxi, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 13 locations

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Small Cell Lung Cancer

Interventions: Drug: BL-B01D1
Drug: SI-B003

First Posted Date: 2023-06-29

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 100

Registration Number: NCT05924841

Locations: 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: BL-B01D1
Drug: Osimertinib Mesylate Tablets

First Posted Date: 2023-05-30

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 114

Registration Number: NCT05880706

Locations: 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China

A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Recurrent or Metastatic Gynecological Malignancies

Phase 1

Recruiting

Conditions: Solid Tumor
Gynecological Malignant Tumor

Interventions: Drug: BL-B01D1

First Posted Date: 2023-04-07

Last Posted Date: 2025-05-07

Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Target Recruit Count: 32

Registration Number: NCT05803018

Locations: 🇨🇳
Fudan University ShangHai Cancer Center, Shanghai, Shanghai, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy